Regulatory News:
TME Pharma N.V. , a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment , announced today that the annual.
Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME) (Paris:ALTME),a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment
TME Pharma Publishes 2023 Financial Results and Provides Operating Update finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Two of six patients receiving NOX-A12 in combination with bevacizumab and radiotherapy exceeded 24-month survival since the start of therapy
This survival compares favorably to the 5% survival.
TME Pharma N V : TME Pharma Announces 33% of Patients Receiving NOX-A12 in Combination With Bevacizumab and Radiotherapy Achieve Two-Year Survival in GLORIA Phase 1/2 Trial in Brain Cancer finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.